Drug and Therapeutics Bulletin 1999;37:57-58; doi:10.1136/dtb.1999.37857
Copyright © 1999 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

{blacktriangledown}Deflazacort - an alternative to prednisolone?

Relevant BNF section: 6.3.2

{blacktriangledown}Deflazacort (Calcort - Shire) is an oral corticosteroid licensed for use in adults and children. When deflazacort first became available last year, the manufacturer claimed that the drug had a lower incidence of steroid-induced unwanted effects compared with prednisolone. However, this claim was later withdrawn at the request of the Medicines Control Agency following its review of the cited data.1 Current promotional material claims simply that deflazacort is "a new choice of oral steroid". Here we discuss whether deflazacort offers any advantages over established corticosteroid therapy.




This article has been cited by other articles:


Home page
 Br J AnaesthHome page
G. R. McAnulty, H. J. Robertshaw, and G. M. Hall
Anaesthetic management of patients with diabetes mellitus
Br. J. Anaesth., July 1, 2000; 85(1): 80 - 90.
[Full Text] [PDF]


About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1999 BMJ Publishing Group Ltd.